ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 156 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q3 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $246 | -10.5% | 9,646 | +0.8% | 0.00% | – |
| Q2 2023 | $275 | -25.1% | 9,574 | -37.4% | 0.00% | – |
| Q1 2023 | $367 | +41.7% | 15,300 | 0.0% | 0.00% | – |
| Q4 2022 | $259 | -99.9% | 15,300 | -0.1% | 0.00% | – |
| Q3 2022 | $227,000 | -5.4% | 15,309 | +0.3% | 0.00% | – |
| Q2 2022 | $240,000 | -41.7% | 15,260 | -0.1% | 0.00% | – |
| Q1 2022 | $412,000 | -27.1% | 15,274 | -0.0% | 0.00% | -100.0% |
| Q4 2021 | $565,000 | -22.8% | 15,279 | -0.2% | 0.00% | 0.0% |
| Q3 2021 | $732,000 | +21.0% | 15,314 | -14.3% | 0.00% | 0.0% |
| Q2 2021 | $605,000 | -22.0% | 17,868 | -5.0% | 0.00% | 0.0% |
| Q1 2021 | $776,000 | -10.1% | 18,800 | -5.5% | 0.00% | 0.0% |
| Q4 2020 | $863,000 | +67.6% | 19,900 | +65.8% | 0.00% | 0.0% |
| Q3 2020 | $515,000 | -8.2% | 12,000 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $561,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 456,390 | $5,541,000 | 3.62% |
| DAFNA Capital Management LLC | 173,914 | $1,890,000 | 0.65% |
| One68 Global Capital, LLC | 19,861 | $216,000 | 0.47% |
| Diametric Capital, LP | 51,982 | $565,000 | 0.41% |
| ARK Investment Management | 1,383,756 | $15,041,000 | 0.38% |
| EAM Investors, LLC | 52,833 | $574,000 | 0.13% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 31,404 | $341,000 | 0.05% |
| Nikko Asset Management Americas, Inc. | 280,548 | $3,050,000 | 0.05% |
| MGO ONE SEVEN LLC | 14,900 | $161,000 | 0.04% |
| Qube Research & Technologies Ltd | 67,702 | $736,000 | 0.02% |